| Literature DB >> 26475706 |
Benson C Iweriebor1,2, Chinwe J Iwu3,4, Larry C Obi5, Uchechukwu U Nwodo6,7, Anthony I Okoh8,9.
Abstract
BACKGROUND: Shiga toxin-producing Escherichia coli (STEC) O157:H7 is a well-recognized cause of bloody diarrhea and hemolytic-uremic syndrome (HUS). The ability of STEC strains to cause human disease is due to the production of Shiga toxins. The objectives of this study were to determinate the prevalence, serotypes, antibiotic susceptibility patterns and the genetic capability for Shiga toxin production in Escherichia coli (STEC) strains isolated from dairy cattle farms in two rural communities in the Eastern Cape Province of South Africa.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26475706 PMCID: PMC4609099 DOI: 10.1186/s12866-015-0553-y
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Primers used in PCR detection of Shiga toxin genes and determination of serotypes
| Target gene | Primer sequences 5′-3′ | Size of product (bp) | Reference |
|---|---|---|---|
|
| STx1-F TTC GCT CTG CAA TAG GTA | 555 | [ |
| STx1-R TTC CCC AGT TCA ATG TAA GAT | |||
|
| STx2-F GTG CCT GTT ACT GGG TTT TTC TTC | 118 | [ |
| STx2-R AGG GGT CGA TAT CTC TGT CC | |||
|
| rfbE-F TTT CAC ACT TAT TGG ATG GTC TCA A | 88 | [ |
| rfbE-R CGA TGA GTT TAT CTG CAA GGT GAT |
Primers used to profile β-lactamases, tet(A) and strA genes in Escherichia coli
| Gene detected | Primer sequence (5′- 3′) | Size (bp) | Reference |
|---|---|---|---|
|
| CF- TCG GGG AAA TGT GCG CG | ||
| DR-TGC TTA ATC AGT GAG GCA CC | 971 | [ | |
|
| OS-5 F- TTA TCT CCC TGT TAG CCA CC | ||
| OS-6R-GAT TTG CTG ATT TCG CTC GG | 795 | [ | |
|
| MA-1 F-SCS ATG TGC AGY ACC AGT AA | 158 | |
| MA-2R- CCG CRA TAT GRT TGG TGG TG | [ | ||
|
| M9UF-ATG GTG ACA AAG AGA GTG CA | 863 | |
| M9LR-CCC TTC GGC GAT GAT TCT C | [ | ||
|
| M13UF-GGT TAA AAA ATC ACT GCG TC | 863 | |
| M13LR-TTG GTG ACG ATT TTA GCC GC | [ | ||
|
| AmpC1F-AAT GGG TTT TCT ACG GTC TG | ||
| AmpC2R-GGG CAG CAA ATG TGG AGC AA | 191 | [ | |
|
| casFF-CGA CTT CCA TTT CCC GAT GC | ||
| casBR -GGA CTC TGC AAC AAA TAC GC | 1052 | [ | |
|
| CF1F-ATGATGAAAAAATCGTTATGC | ||
| CF2R-TTGTAGCTTTTCAAGAATGCGC | 507 | [ | |
| tet(A) | TetA-F-GGCCTCAATTTCCTGACG | ||
| TetA-R-AAGCAGGATGTAGCCTGTGC | 372 | [ | |
| strA | strA-F-CTTGGTGATAACGGCAATTC | ||
| strA-R-CCAATCGCAGATAGAAGGC | 548 | [ |
Prevalence of Shiga toxin genes among the STEC O157 isolates
| Serogroup |
|
| Prevalence of Shiga toxin genes |
|---|---|---|---|
| O157 ( | + | - | 37 (44 %) |
| - | + | 38 (45.3 %) | |
| + | + | 9 (10.7 %) |
Fig. 1Gel image of amplified PCR products from study isolates with primers designed for stx1 virulent gene. Lane 1 is the MWM (100 bp), lane 2 is the negative control (PCR mix without DNA) with lane 3 as positive control (E. coli ATCC 35150) while lanes 4 to 13 are stx1 (555 bp) gene amplified from O157 isolates
Antibiotic susceptibility pattern of E. coli O157:H7 (n = 95)
| Antibiotics class | Antimicrobial agents | Code | Potency (μg) | R | S |
|---|---|---|---|---|---|
| N (%) | |||||
| Tetracycline | Tetracycline | T | 30 | 92 (96.8) | 3 (3.3) |
| Oxytetracycline | OT | 30 | 90 (94.7) | 5 (5.3) | |
| Penicillin | Ampicillin | AMP | 10 | 90 (94.7) | 5 (5.3) |
| Amoxicillin/Claculanic acid | AUG | 10 | 80 (84.2) | 15 (15.8) | |
| Cephalospirines | Cephalothin | KF | 30 | 90 (94.7) | 5 (5.3) |
| Ceftazidime | CAZ | 30 | 30 (32) | 65 (78) | |
| Cefuroxime | CXM | 30 | 78 (82) | 17 (18) | |
| Carbapenems | Imipenem | IMI | 10 | 0 (0) | 95 (100) |
| Phenicols | Chloramphenicol | CIP | 10 | 85 (89.5) | 10 (10.5) |
| Aminoglycosides | Amikacin | AK | 30 | 6 (6.3) | 89 (93.7) |
| Kanamycin | K | 10 | 5 (5.3) | 90 (94.7) | |
| Streptomycin | S | 10 | 80 (80.2) | 15 (15.8) | |
| Gentamycin | GM | 10 | 8 (8.4) | 87 (91.6) | |
| Quinolones | Ciprofloxacin | CIP | 5 | 12 (12.6) | 83 (87.4) |
| Norfloxacin | NOR | 10 | 10 (10.5) | 85 (89.5) | |
| Enrofloxacin | ENR | 10 | 7 (7.4) | 88 (92.6) | |
| Foliate pathway inhibitor | Sulfamethazole/Trimethoprim | TS | 25 | 80 (80.2) | 15 (15.8) |
R Resistant, S Susceptible, T Tetracycline, OT Oxytetracycline, AMP Ampicillin, AUG Amoxilcillin/clavulanic acid, KF Cephalothin, CXM Cefuroxime, CAZ Ceftazidime, C Chloramphenicol, IMI Imipenem, AK Amikacin, K Kanamycin, S Streptomycin GM Gentamycin, CIP Ciprofloxacin, NOR Norfloxacin, ERN Enrofloxacin, TS Sulphamethoxazole/Trimethoprim
PCR targeted genes and their percentage occurrence among the isolates
| Resistance gene profiled | Percentage of amplified genes |
|---|---|
|
| 90 % |
|
| 70 % |
|
| 65 % |
|
| 70 % |
|
| 80 % |
|
| 27 % |
|
| 0 % |
|
| 0 % |
|
| 0 % |
|
| 0 % |
Fig. 2Agarose gel images of amplicons obtained from PCR with primers designed for strA resistance gene of E. coli isolates recovered from this study. Lane 1 is molecular size markers (100 bp), lane 2 is negative control (PCR mix without DNA) while lanes 3 to 18 are strA (548 bp) gene from O157 strains isolated in this study
Fig. 3Agarose gel image of amplicons obtained from PCR with primers designed for bla-ampC resistance gene of E. coli isolates recovered from this study. Lane 1 is molecular size markers (100 bp), lane 2 is negative control (PCR mix without DNA) while lanes 3 to 18 are bla-ampC (198 bp) gene from O157 strains isolated in this study
Fig. 4Gel image of amplicons obtained from multiplex PCR with primers designed for bla-CMY and bla-CXT-M resistance genes of E coli isolates recovered from this study. Lane 1 is molecular size markers (100 bp), lane 2 is negative control (PCR mix without DNA) while lanes 3 to 18 are bla-CMY (507bp) and bla-CXT-M (158 bp) genes from O157 strains isolated in this study